The Predictive and Diagnostic Value of Cystatin C and High Sensitive Troponin

Acute Coronary Syndrome Clinical Trial

Official title:

The Predictive and Diagnostic Value of Using Cystatin C and High Sensitive Troponin Level Together for Diagnosis of ACS in Patients With Chronic Kidney Disease Coming to Emergency Department With Chest Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05303441
• Other study ID #: AnkaraDiskapiTRH
• Status: Recruiting
• Start date: March 7, 2022
• Est. completion date: February 1, 2023

Study information

• Verified date: March 2022
• Source: Ankara Diskapi Training and Research Hospital
• Contact: bedriye müge sönmez, assoc. prof.
• Phone: +903125962470
• Email: mugesonmez06[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our study is planning to evaluate patients with chronic kidney disease who come to the emergency department with chest pain. Estimated GFR (cisGFR) with cystatin and estimated GFR (creaGFR) with creatinine will be calculated. Symptoms, ECG and troponin values of patients will be evaluated for diagnosis of acute coronary syndrome

Description:

Our study is planning to evaluate patients with chronic kidney disease who come to the emergency department with chest pain. Estimated GFR (cisGFR) with cystatin and estimated GFR (creaGFR) with creatinine will be calculated. Symptoms, ECG and troponin values of patients will be evaluated for diagnosis of acute coronary syndrome and the final diagnosis of AMI will be adjudicated by 2 independent cardiologists.Serial troponin measurements and eGFR values will be proportioned. These values the will be evaluated and compared for patients with acute coronary syndrome(culprit lesion on conventional coronary angiography) and non-ACS ones . With these data we aim to facilitate the diagnosis of acute coronary syndrome,increase the specificity and sensitivity of cardiac troponins for the diagnosis of acute coronary syndrome of patients with chronic kidney disease, increase the utility of high sensitive troponins for patients with chronic kidney disease. Again, with these data, it is aimed to reduce the number of false negative and false positive diagnosis of acute coronary syndrome .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 172
• Est. completion date: February 1, 2023
• Est. primary completion date: January 7, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age over 18,

2. chronic kidney diease having chest pain or equivalent of chest pain (dyspnea, diaphoresis, syncope, nausea, vomiting) -

Exclusion Criteria:

1. STEMI,

2. age less than 18,

3. missing data,

4. patients referred to or accepted from another medical facility

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Chronic Kidney Diseases
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Procedure:
• percutaneous coronary intervention
conventional coronary angiography

Locations

Country	Name	City	State
Turkey	Diskapi Research and Training Hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara Diskapi Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anticipated ACS	The role of cystatin C in diagnosis acute coronary syndrome when used with troponin in patients with chronic renal failure.	time passed until PCI (percutaneous coronary intervention) (pre-intervention) or admission to hospital
Primary	exclusion of acs	exclusion of ACS according to current guidelines	time passed during emergency department visit until discharge avarage of 3-6 hours